![Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs]()
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugsStrand, Vibeke; de Vlam, Kurt; Covarrubias-Cobos, Jose A; Mease, Philip J; Gladman, Dafna D; Graham, Daniela; Wang, Cunshan; Cappelleri, Joseph C; Hendrikx, Thijs; Hsu, Ming-Ann · RMD Open · 2019